



PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/730,614		
		Filing Date	December 8, 2003		
		First Named Inventor	Jun LI		
		Art Unit	1635		
		Examiner Name	GIBBS, Terra C.		
Sheet	1	of	1	Attorney Docket Number	9/263

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
TCG		A. O'MAHONY, et al. "Activation of the Heterodimeric IκB Kinase alpha (IKKalpha)-IKKbeta Complex is Directional: IKKalpha Regulates IKKbeta under both Basal and Stimulated Conditions", Mol. and Cell.Bio., Vol. 20, No. 4, pp 1170-1178, 2000	
↓		I. S. BHULLAR, et al. "Fluid Shear Stress Activation of IκB Kinase is Integrin-dependent", J. Bio. Chem. Vol. 273, No. 46, pp 30544-30549, 1998	
↓		M. C.-T. HU, et al. "IκB kinase-alpha and -beta genes are coexpressed in adult and embryonic tissues but localized to different human chromosomes", Gene, Vol. 222, pp 31-40, 1998	
↓		J. D. THOMPSON "Applications of antisense and siRNAs during preclinical drug development", Drug Discovery Today, Vol. 7, No. 17, pp 912-917, 2002	
TCG		S. AGRAWAL, et al. "Antisense therapeutics: is it as simple as complementary base recognition?", Mol. Med. Today, Vol. 6, pp 72-81, 2000	

Examiner Signature	/Terra Cotta Gibbs/	Date Considered	06/20/2006
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.